Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Statement Regarding Arix Bioscience plc

4 May 2022 18:39

RNS Number : 3688K
Acacia Research Corporation
04 May 2022
Ā 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

Ā 

Ā 

THIS ANNOUNCEMENT IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE").

Ā 

Ā 

FOR IMMEDIATE RELEASE

Ā 

Ā 

4 May 2022

Ā 

Acacia Research Corporation ("Acacia")

Ā 

Statement regarding Arix Bioscience plc ("Arix" or "the Company")

Ā 

Acacia―the permanent capital platform with investments in the life sciences sector―announcesĀ that it has notified Arix of an acquisition of a further 646,832 shares in the Company, increasing its ownership to 27,182,317 shares, which represents approximately 21.0% of Arix's issued share capital.

Ā 

Acacia has notified the Board of Arix that it does not intend to make an Offer for Arix and will be bound by that statement for the purposes of Rule 2.8 of the UK's Takeover Code.

Ā 

Clifford Press, Chief Executive Officer & President of Acacia, stated:

Ā 

"We are pleased to take this opportunity to increase our shareholding in Arix. In the last year, Arix has undertaken a number of steps to improve its performance and corporate governance and we remain fully supportive of management's strategy."

Ā 

Rule 2.8 statement

Ā 

Acacia confirms that it does not intend to make an offer for Arix. This is a statement to which Rule 2.8 of the Takeover Code (the "Code") applies. Under Note 2 on Rule 2.8 of the Code, Acacia reserves the right to set the restrictions in Rule 2.8 aside in any of the following circumstances:

Ā 

a) with the agreement of the board of Arix;

Ā 

b) if a third party announces a firm intention to make an offer for Arix;

Ā 

c) if Arix announces a Rule 9 waiver proposal (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse takeover (as defined in the Code); or

Ā 

d) if there has been a material change of circumstances (as determined by the Takeover Panel).

Ā 

Contact details

Ā 

Investor Contact:

FNK IR

Rob Fink, 646-809-4048

rob@fnkir.com

Ā 

Media Contact:

Longacre Square Partners

Greg Marose, 646-386-0091

gmarose@longacresquare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
STRAIMRTMTJMBMT
Date   Source Headline
29th Jul 20215:30 pmEQSTransaction in own shares
28th Jul 20215:30 pmEQSTransaction in own shares
27th Jul 20215:05 pmEQSTransaction in own shares
27th Jul 20217:02 amEQSArtios raises $153m in Series C financing
26th Jul 20215:00 pmEQSTransaction in own shares
23rd Jul 20215:05 pmEQSTransaction in own shares
22nd Jul 20215:07 pmEQSTransaction in own shares
21st Jul 20215:19 pmEQSTransaction in own shares
21st Jul 20217:00 amEQSNotice of Results
20th Jul 20215:14 pmEQSTransaction in own shares
19th Jul 20215:19 pmEQSTransaction in own shares
16th Jul 20215:20 pmEQSTransaction in own shares
15th Jul 20215:19 pmEQSTransaction in own shares
14th Jul 20215:08 pmEQSTransaction in own shares
14th Jul 20219:00 amEQSImara announces pricing of public offering
14th Jul 20217:00 amEQSTransaction in own shares
12th Jul 20215:33 pmEQSTransaction in own shares
8th Jul 20215:15 pmEQSTransaction in own shares
7th Jul 20215:37 pmEQSTransaction in own shares
6th Jul 20215:26 pmEQSTransaction in own shares
6th Jul 20217:01 amEQSTeam changes
5th Jul 20214:59 pmEQSTransaction in own shares
1st Jul 20215:09 pmEQSTransaction in own shares
1st Jul 20217:01 amEQSTotal Voting Rights
30th Jun 20215:00 pmEQSTransaction in own shares
29th Jun 20214:54 pmEQSTransaction in own shares
28th Jun 20215:38 pmEQSTransaction in own shares
25th Jun 20214:57 pmEQSTransaction in own shares
24th Jun 20215:21 pmEQSTransaction in own shares
23rd Jun 20215:06 pmEQSTransaction in own shares
22nd Jun 20215:18 pmEQSTransaction in own shares
21st Jun 20215:06 pmEQSTransaction in own shares
18th Jun 20215:13 pmEQSTransaction in own shares
17th Jun 20215:12 pmEQSTransaction in own shares
16th Jun 20215:25 pmEQSTransaction in own shares
15th Jun 20215:40 pmEQSTransaction in own shares
14th Jun 20215:20 pmEQSTransaction in own shares
14th Jun 20212:55 pmEQSResults of Annual General Meeting
11th Jun 20215:01 pmEQSTransaction in own shares
11th Jun 20211:05 pmEQSClinical portfolio update
10th Jun 20215:26 pmEQSTransaction in own shares
9th Jun 20215:15 pmEQSTransaction in own shares
8th Jun 20215:14 pmEQSTransaction in own shares
7th Jun 20215:08 pmEQSTransaction in own shares
4th Jun 20215:13 pmEQSTransaction in own shares
4th Jun 20213:25 pmEQSHarpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting
3rd Jun 20215:34 pmEQSTransaction in own shares
2nd Jun 20215:12 pmEQSTransaction in own shares
1st Jun 20215:35 pmEQSTransaction in own shares
1st Jun 20217:01 amEQSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.